Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT07517640 Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT07517640
Not Yet Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part in the study voluntarily
  • You are 18 years old or older at the time of signing the consent form
  • You have been diagnosed with early-stage non-small cell lung cancer (a type of lung cancer) confirmed by a tissue or cell sample, or you have multiple tumour spots in the lung or a single tumour that has come back in the lung tissue
  • Your lung cancer has been shown by genetic testing to have certain specific changes (mutations) in a gene called EGFR, such as Exon 19 deletion, L858R, or other related changes
  • Your general health and ability to carry out daily activities is at a reasonable level (confirm with trial site)
  • You have been assessed by a team of doctors as not being suitable for surgery, or you have chosen not to have surgery
  • Your lung tumour(s) can be treated with either ablation (a procedure that destroys tumour tissue using heat or cold) or radiotherapy (radiation treatment)
  • Your liver, kidneys, and other major organs are functioning well enough to take part

Who may not be able to join:

  • You have had a severe allergic reaction in the past to a type of medicine called a monoclonal antibody, or to ingredients used in the study drug
  • You have a medical reason why you cannot have ablation or radiotherapy
  • Your tumour cannot be treated with radiotherapy in a way that meets the required safety standards for protecting nearby healthy organs (confirm with trial site)
  • You have had an active infection that needed treatment with medicines (taken by mouth or into a vein) within the 14 days before starting the study
  • You have hepatitis B or hepatitis C with signs that the virus is currently active in your body
  • You received radiotherapy aimed at curing your cancer within the 3 months before starting the study
  • You had a major surgical procedure within 28 days before starting the study (defined as surgery needing at least 3 weeks of recovery time)
  • You are currently taking part in another clinical trial, or you took part in one involving a drug or medical device within the past 3 months (or within a certain timeframe based on the previous drug used — confirm with trial site)
  • The trial doctor believes there is any other reason that makes it unsafe or unsuitable for you to join

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Xuefei Hu, Shanghai Pulmonary Hospital, Shanghai, China

Phone: +86 21 65115006

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 February 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-year EFS rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov